Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent

BACKGROUND: Vedolizumab (VDZ) is currently licensed for use in adults for the treatment of inflammatory bowel disease (IBD). We aimed to investigate the clinical course of pediatric-onset IBD following treatment with VDZ as more than a secondary biologic agent. We also evaluated factors associated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Sujin, Kim, Eun Sil, Kwon, Yiyoung, Kim, Mi Jin, Choe, Yon Ho, Choe, Byung-Ho, Kang, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512676/
https://www.ncbi.nlm.nih.gov/pubmed/36163478
http://dx.doi.org/10.3346/jkms.2022.37.e282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512676/
https://www.ncbi.nlm.nih.gov/pubmed/36163478
http://dx.doi.org/10.3346/jkms.2022.37.e282

Ejemplares similares